Strides Pharma to acquire, in-license Sandoz generic brands in Africa for $12 million upfront

The upfront consideration for the transaction is $12 million, payable at closing. In addition, Strides will make royalty payments to Sandoz based on a percentage of net sales of distribution products. Shares of Strides Pharma Science Ltd ended at ₹876.55,…








